Current status of precision medicine in pediatric oncology in Spain: A consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

• P. Gargallo ^[4] ; F. Bautista ^[5] ; A. Juan-Ribelles ^[6] ; E. Izquierdo ^[7] ; A. Soriano ^[8] ; T. de Rojas ^[7] ; A. Escudero ^[9] ; C. Lavarino ^[1] ; P. Solano ^[10] ; R. Hladun ^[11] ; A. Rubio-San-Simón ^[5] ; I. Martínez-Romera ^[12] ; I. Calabria ^[13] ; N. G. Olaciregui ^[1] ; A. Castañeda-Heredia ^[1] ; E. de Álava ^[14] ; A. Pérez-Martínez ^[2] ; I. Astigarraga ^[15] ; A. Patiño-García ^[16] ; J. Alonso ^[17] ; A. Fernández-Teijeiro ^[3] ; A. Cañete ^[6] ; L. Moreno ^[11]
  1. [1] Hospital Sant Joan de Deu

     Hospital Sant Joan de Deu

     Barcelona, España

     
  2. [2] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  3. [3] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  4. [4] Research Institute Hospital La Fe, Valencia, Spain Oncology Department, Health in Code Group, Paterna, Valencia, Spain
  5. [5] Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain
  6. [6] Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain
  7. [7] Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children’s University Hospital Niño Jesús, Madrid, Spain
  8. [8] Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
  9. [9] Translational Research in Pediatric Oncology, Hematopoietic Stem Cell Transplantation, Cell Therapy, INGEMM-IdiPAZ, La Paz University Hospital, Madrid, Spain
  10. [10] Department of Pediatric Oncology, Hospital Infantil Virgen del Rocio, Sevilla, Spain
  11. [11] Group of Translational Research in Child and Adolescent Cancer, Vall d’Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain Vall d’Hebron University Hospital, Barcelona, Spain
  12. [12] Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, Madrid, Spain
  13. [13] Oncology Department, Health in Code Group, Paterna, Valencia, Spain
  14. [14] Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Sevilla/CIBERONC, Sevilla, Spain
  15. [15] Servicio de Pediatria, Bio Cruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain Departamento de Pediatria, Universidad del Pais Vasco UPV/EHU, Leioa, Spain
  16. [16] Laboratory and Department of Pediatrics, University Clinic of Navarra and Solid Tumor Area, CIMA, IdiSNA, Pamplona, Spain
  17. [17] Instituto de Investigación de Enfermedades Raras and U758 (CB06/07/1009), CIBERER, Instituto de Salud Carlos III, Unidad de Tumores Sólidos Infantiles, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 5 (May), 2022, págs. 809-815
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • The study analyzes the current status of personalized medicine in pediatric oncology in Spain. It gathers national data on the tumor molecular studies and genomic sequencing carried out at diagnosis and at relapse, the centers that perform these studies, the technology used and the interpretation and clinical applicability of the results. Current challenges and future directions to achieve a coordinated national personalized medicine strategy in pediatric oncology are also discussed. Next generation sequencing-based (NGS) gene panels are the technology used in the majority of centers and financial limitations are the main reason for not incorporating these studies into routine care. Nowadays, the application of precision medicine in pediatric oncology is a reality in a great number of Spanish centers. However, its implementation is uneven and lacks standardization of protocols; therefore, national coordination to overcome the inequalities is required. Collaborative work within the Personalized Medicine Group of SEHOP is an adequate framework for encouraging a step forward in the effort to move precision medicine into the national healthcare system.